ZA202405048B - Pyrazine amide derivatives - Google Patents

Pyrazine amide derivatives

Info

Publication number
ZA202405048B
ZA202405048B ZA2024/05048A ZA202405048A ZA202405048B ZA 202405048 B ZA202405048 B ZA 202405048B ZA 2024/05048 A ZA2024/05048 A ZA 2024/05048A ZA 202405048 A ZA202405048 A ZA 202405048A ZA 202405048 B ZA202405048 B ZA 202405048B
Authority
ZA
South Africa
Prior art keywords
pyrazine amide
amide derivatives
pyrazine
amide derivative
compounds
Prior art date
Application number
ZA2024/05048A
Other languages
English (en)
Inventor
Richard Yichong Huang
Jr Thomas Martin Kirrane
Vanessa Marx
Anne-Catherine Mata
Christopher Ronald Sarko
Benjamin Robert Taft
Fumiaki Yokokawa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA202405048B publication Critical patent/ZA202405048B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fuel Cell (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2024/05048A 2022-03-24 2024-06-27 Pyrazine amide derivatives ZA202405048B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263269879P 2022-03-24 2022-03-24
PCT/IB2023/052827 WO2023180964A1 (en) 2022-03-24 2023-03-22 Pyrazine amide derivatives

Publications (1)

Publication Number Publication Date
ZA202405048B true ZA202405048B (en) 2025-09-25

Family

ID=85979464

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/05048A ZA202405048B (en) 2022-03-24 2024-06-27 Pyrazine amide derivatives

Country Status (10)

Country Link
US (1) US20250197376A1 (https=)
EP (1) EP4499631A1 (https=)
JP (1) JP2025509917A (https=)
CN (1) CN118591538A (https=)
AU (1) AU2023240513A1 (https=)
CA (2) CA3181279A1 (https=)
CO (1) CO2024010469A2 (https=)
DO (1) DOP2024000149A (https=)
WO (1) WO2023180964A1 (https=)
ZA (1) ZA202405048B (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137081A2 (en) * 2008-05-07 2009-11-12 Massachusetts Institute Of Technology Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase
CN102089278A (zh) * 2008-06-11 2011-06-08 Irm责任有限公司 用于治疗疟疾的化合物和组合物
ES2921576T3 (es) * 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
LT2925757T (lt) * 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
WO2016089977A1 (en) * 2014-12-03 2016-06-09 Celgene Corporation Substituted indazole compounds, compositions thereof, and methods of treatment therewith
CN110023312A (zh) * 2016-10-13 2019-07-16 由卫生与公众服务部部长代表的美利坚合众国 阻止疟疾寄生虫传播的化合物和方法
WO2018081863A1 (en) * 2016-11-04 2018-05-11 University Of Wollongong 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF
EP3790878A1 (en) * 2018-05-11 2021-03-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Quinoline compounds and their preparation and use as antimalarial agents

Also Published As

Publication number Publication date
WO2023180964A1 (en) 2023-09-28
EP4499631A1 (en) 2025-02-05
CA3181279A1 (en) 2023-09-24
CN118591538A (zh) 2024-09-03
JP2025509917A (ja) 2025-04-11
US20250197376A1 (en) 2025-06-19
CO2024010469A2 (es) 2024-08-08
AU2023240513A1 (en) 2024-07-18
CA3251003A1 (en) 2023-09-28
DOP2024000149A (es) 2024-08-30

Similar Documents

Publication Publication Date Title
CR20230566A (es) Derivados de triazina y su uso en el tratamiento del cáncer
MX2023012054A (es) Inhibidor derivado heterociclico y metodo de preparacion y su aplicacion.
MY210086A (en) Pharmaceutical compounds
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2007013216A (es) Derivados de amida substituida como inhibidores de la proteina de cinasa.
MY132789A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
MXPA05009304A (es) Derivados de indol utiles para el tratamiento de enfermedades.
EA200870282A1 (ru) Производные амина
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
CR20230382A (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
TW200505865A (en) Compounds useful for the treatment of diseases
GEAP202415866A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2023011829A (es) Derivados de uracilo como inhibidores de trpa1.
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
ZA202400821B (en) Inhibitors of transglutaminases
WO2024099364A3 (en) Fused multicyclic compounds and their use as parp1 inhibitors